PTC submits EU application for Translarna for cystic fibrosis

The European Medicines Agency (EMA) has validated the submission of a variation for a new indication for PTC Therapeutics’ Translarna (ataluren) for the treatment of nonsense mutation cystic fibrosis (nmCF) for patients not taking Continue reading PTC submits EU application for Translarna for cystic fibrosis

The High Cost—and Difficult Ethics—of Personalized Medicine

Spending on pharmaceuticals is surging again, up 13% in 2014. Surveys show the public is increasingly concerned about the affordability of drugs. Part of the reason for their high costs is the advent of precision (or personalized) medicine, Continue reading The High Cost—and Difficult Ethics—of Personalized Medicine